Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics

Brand Names


Austria: Pariet; Belgium: Pariet; Bulgaria: Pariet; Cyprus: Pariet; Denmark: Pariet; Finland: Pariet; France: Alfence, Pariet; Germany: Pariet; Greece: Pariet; Hungary: Florentis, Pariet, Rabeprazol, Rabiprex; Ireland: Pariet, Rabeprazole; Italy: Pariet; Lithuania: Pariet; Luxembourg: Pariet; Malta: Pariet; Netherlands: Pariet; Portugal: Pariet, Rabeprazol, Ralic; Spain: AcipHex, Pariet; Sweden: Pariet; UK: Pariet.

North America

Canada: Pariet, Rabeprazole; USA: AcipHex.

Latin America

Argentina: Pariet, Rabec; Brazil: Pariet; Mexico: Pariet.


Japan: Pariet.

Drug combinations


Rabeprazole Sodium: C~18~H~20~N~3~NaO~3~S. Mw: 381.42. (1) 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt; (2) 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]benzimidazole sodium salt. CAS-117976-90-6; CAS-117976-89-3 (rabeprazole)(1995).

Pharmacologic Category

Antiulcer Agents and Acid Suppressants; Proton-pump Inhibitors; Substituted Benzimidazole. (ATC-Code: A02BC04).

Mechanism of action

Suppresses gastric acid secretion by inhibiting parietal cell H^+^/K^+^ ATP pump.

Therapeutic use

Short-term (4-8 weeks) treatment and maintenance of erosive or ulcerative gastroesophageal reflux disease (GERD). Symptomatic GERD. Short-term (up to 4 weeks) treatment of duodenal ulcers. Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. H. pylori eradication (in combination with amoxicillin and clarithromycin).

Pregnancy and lactiation implications

Use during pregnancy only if clearly needed. Not recommended in nursing women.

Unlabeled use

Maintenance of duodenal ulcer.


Hypersensitivity to rabeprazole, substituted benzimidazoles (i.e. esomeprazole, lansoprazole, omeprazole, pantoprazole), or any component of the formulation.

Warnings and precautions

Long-term omeprazole therapy caused atrophic gastritis (by biopsy); this may also occur with rabeprazole. No reports of enterochromaffin-like cell carcinoids, dysplasia, or neoplasia occurred. Relief of symptoms does not preclude presence of gastric malignancy. Use of proton pump inhibitors may increase risk of these infections. Use caution in severe hepatic impairment.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart